Transurethral electric resection plus arterial catheterization chemotherapy for T2a bladder carcinoma

Abstract

Clinical data of 23 patients with T2a bladder cancer admitted from March 2008 to August 2013 were retrospectively analyzed. Among 23 patients, 11 cases were treated with transurethral resection (TURBT) plus arterial catheterization chemotherapy (study group) and 12 cases were treated with radical cystectomy (control group). The overall survival time and recurrence free survival time of two groups were compared. Patients in study group were followed up for 20-68 months, recurrence occurred in 5 cases (5/11), including 4 cases of invasive recurrence; patients in control group were followed up for 2~86 months, 1 case had superficial recurrent and underwent TURBT, 2 cases dead due to bladder tumor. During the course of chemotherapy, the main adverse effects were digestive reaction (7/11), fever (4/11), bone marrow suppression (2/11), symptomatic treatment was given, which was tolerated. There were no significant differences in overall survival time and recurrence free survival time between two groups (P>0.05). The quality of life of study group was better than that of control group (P<0.05). It is suggested that the arterial interventional chemotherapy combined with transurethral resection for T2a stage invasive bladder cancer has a certain curative effect with the advantage of preservation of bladder function and higher quality of life. Key words: Urinary bladder neoplasms; Drug therapy, interventional; Prognosis